🦠 Meningococcal Disease and Vaccination: From Discovery to Modern Prevention—A Focus on Serogroup B and Global Policy Gaps

✍️ MFCTA Science Update – Expert Review


Abstract

Invasive disease caused by Neisseria meningitidis remains a rapidly progressive and potentially fatal condition despite advances in antimicrobial therapy and vaccination. Over the past century, the epidemiology of meningococcal disease has shifted significantly, with serogroup B (MenB) now predominating in high-income countries such as the United Kingdom. This review traces the historical discovery of meningococcus, the evolution of vaccine technologies, and contrasts implementation strategies between the UK and Sri Lanka.


Introduction

Meningococcal disease, caused by Neisseria meningitidis, remains an uncommon but potentially catastrophic infection characterised by rapid progression from non-specific symptoms to meningitis and septicaemia. Despite advances in antimicrobial therapy and vaccination, the disease continues to pose a significant clinical challenge due to its unpredictable onset and high case fatality rate.

In the United Kingdom, the epidemiology of invasive meningococcal disease (IMD) has evolved substantially over the past two decades. Following the successful introduction of the MenC conjugate vaccine in 1999 and the MenACWY adolescent programme, the incidence of serogroup C disease has declined dramatically, with sustained herd immunity effects [3,6]. More recently, the implementation of the MenB (4CMenB) vaccine into the infant immunisation schedule in 2015 has led to a measurable reduction in serogroup B disease among vaccinated cohorts [5].

However, serogroup B remains the leading cause of IMD in the UK, accounting for the majority of laboratory-confirmed cases in recent years. Current surveillance data indicate that overall incidence remains low—typically <1 case per 100,000 population annually—but the burden is disproportionately higher in:

In recent surveillance cycles, England has reported approximately 400–600 confirmed IMD cases per year, with case fatality rates ranging between 5–10%, and higher mortality associated with septicaemia and delayed presentation. Notably, sporadic increases in serogroup W (MenW) cases during the past decade prompted expansion of the MenACWY programme, illustrating the dynamic nature of meningococcal epidemiology.

Despite the overall decline in incidence, the persistence of serogroup B disease reflects important biological and public health challenges, including:

These observations underscore the need for continued vigilance in clinical recognition and sustained investment in vaccine innovation. Furthermore, the UK experience provides an instructive model when contrasted with regions such as South Asia, including Sri Lanka, where meningococcal vaccination is not routinely implemented and epidemiological data remain sparse.


Historical Perspective

Neisseria meningitidis was first described by Anton Weichselbaum in 1887 following isolation from cerebrospinal fluid of affected patients. Early epidemics in the 20th century, particularly in military populations, drove the development of preventive strategies [1].

Polysaccharide vaccines were introduced in the 1960s–70s but were limited by poor immunogenicity and lack of herd protection [2].


Evolution of Vaccine Technology

Conjugate Vaccines

The introduction of conjugate vaccines in the late 1990s marked a turning point. These vaccines:

The UK introduced the MenC vaccine in 1999, leading to a dramatic decline in serogroup C disease [3].


Serogroup B Vaccine Development

Serogroup B posed a unique challenge due to molecular mimicry with human neural tissues. Advances in reverse vaccinology enabled the development of protein-based vaccines such as:

These vaccines target conserved surface antigens rather than capsular polysaccharides [4].


UK Vaccination Programme

The UK has implemented a comprehensive strategy:

💉 MenB Vaccine


💉 MenACWY Vaccine

Vaccination: Administration and Duration of Protection

Meningococcal vaccines are administered via intramuscular injection, typically into the anterolateral thigh in infants and the deltoid muscle in older children and adults. In the United Kingdom, routine immunisation includes the protein-based MenB vaccine given in infancy (2, 4, and 12 months) and the MenACWY conjugate vaccine administered during adolescence. 

Conjugate vaccines targeting serogroups A, C, W, and Y induce T-cell–dependent immune responses, resulting in durable immunological memory and a reduction in nasopharyngeal carriage, thereby contributing to herd immunity. Protection following MenACWY vaccination is generally sustained for 5–10 years, although booster doses are recommended for individuals at ongoing risk. 

In contrast, MenB vaccines, which target surface-exposed protein antigens, provide effective individual-level protection but have limited impact on carriage and thus do not confer substantial herd immunity. The duration of protection following MenB vaccination is estimated to be 3–5 years, with evidence of waning antibody levels over time. 

Importantly, no single vaccine provides comprehensive coverage against all meningococcal serogroups, necessitating a combined strategy to achieve optimal protection. In settings such as Sri Lanka, where routine meningococcal vaccination is not implemented, population-level immunity remains low, underscoring the need for targeted immunisation strategies and enhanced surveillance.


Sri Lanka: Current Status

Sri Lanka does not include meningococcal vaccines in its national immunisation programme.

Vaccination is limited to:

The absence of routine vaccination, combined with limited surveillance, suggests possible underestimation of disease burden [7].


Public Health Implications

Key gaps include:

Cross-protection and Limitations

Meningococcal vaccines are designed to induce immune responses against specific antigens of Neisseria meningitidis and, as such, do not provide broad protection against unrelated pathogens. However, emerging epidemiological and immunological data suggest that partial cross-protection may occur between closely related species, particularly between N. meningitidis and Neisseria gonorrhoeae, owing to shared outer membrane proteins and conserved antigenic targets. Observational studies have reported a reduction in gonorrhoea incidence following implementation of certain MenB vaccination programmes, although the degree of protection is modest and inconsistent. Importantly, this effect is partial, non-specific, and insufficient for clinical reliance, and it does not extend to phylogenetically distinct organisms such as Treponema pallidum, the causative agent of syphilis. These findings underscore a key principle of vaccinology: while cross-reactivity may confer limited ancillary benefits in closely related organisms, meningococcal vaccines should be regarded as pathogen-specific interventions, and their use does not obviate the need for targeted prevention strategies against other infectious diseases.


Conclusion

While high-income countries such as the UK have achieved significant reductions in meningococcal disease through vaccination, policy and surveillance gaps remain in South Asia. Addressing these disparities is essential to improving global meningococcal disease control.


📚 References